Edition:
India

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.77USD
20 Feb 2018
Change (% chg)

$-0.10 (-2.58%)
Prev Close
$3.87
Open
$3.82
Day's High
$3.97
Day's Low
$3.73
Volume
259,937
Avg. Vol
436,779
52-wk High
$4.71
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​.RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA.  Full Article

Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017.COMPANY HAS INITIATED AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.NELSON CABATUAN, RIGEL'S VICE PRESIDENT, FINANCE WILL SERVE AS COMPANY'S INTERIM PRINCIPAL ACCOUNTING OFFICER.  Full Article

Rigel announces Q3 loss of $0.14 per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces third quarter 2017 financial results and provides company update.Q3 loss per share $0.14.  Full Article

Rigel announces pricing of public offering of common stock
Thursday, 5 Oct 2017 

Oct 4 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces pricing of public offering of common stock.Says public offering of 18.1 million common shares priced at $3.35 per share.  Full Article

Rigel Pharmaceuticals q2 loss per share $0.15
Wednesday, 3 Aug 2016 

Rigel Pharmaceuticals Inc : Q2 loss per share $0.15 . Expects cash, cash equivalents and short-term investments as Of June 30 to be sufficient to fund operations into q3 of 2017 . Rigel pharmaceuticals inc qtrly revenues $13.6 million versus $7.4 million .Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​